EHA 2024 – Chan Cheah
Chan Cheah discusses key aspects of a disease-centered treatment approach for relapsed/refractory CLL, explains how B-cell degraders, compared to BTK inhibitors, can improve management of B cell malignancies, and highlights notable results for the BTK degrader BGB-16673 in relapsed or refractory indolent non-Hodgkin lymphoma.
Here is the full EHA 2024 report.
More posts
Preface – EHA 2024
At the European Hematology Association (EHA) congress held in Madrid, Spain, and virtually from 13th–16th June 2024, world-leading experts from 150 countries presented cutting-edge research and clinical trials. This year, we witnessed significant advancements in the treatment of chronic lymphocytic leukemia (CLL).
